Glucocorticoid Use Tied to CVD Risk in Immune-Mediated Diseases
For patients with six immune-mediated inflammatory diseases, the risk for CVD is increased in association with glucocorticoid dose.
For patients with six immune-mediated inflammatory diseases, the risk for CVD is increased in association with glucocorticoid dose.
A phase 3 study evaluating the efficacy and safety of ruxolitinib for the treatment of COVID-19 did not meet its primary end point.
Researchers evaluated the clinical effect of baricitinib on mortality and morbidity in patients with COVID-19.
Investigators compared automated imaging measures of inflammation with clinical exam assessment of activity in uveitis patients to determine efficacy.
Neurologic disturbances in patients with coronavirus disease 2019 were accompanied by evidence of cytokine release syndrome.
Adult patients with current or previous SARS-CoV-2 can develop a hyperinflammatory syndrome.
Researchers identified factors related to autoantibody positivity and development of inflammatory arthritis/rheumatoid arthritis, based on family history of disease.
Researchers evaluated a specific phenotype of COVID-19-associated hyperinflammation and its association with escalation of patient care.
Researchers assessed clinical and laboratory data of patients with lung involvement in macrophage activation syndrome and severe COVID-19.
Researchers evaluated the possibility of SARS-CoV-2 infection accelerating the onset of an autoimmune rheumatic disease.